CureVac starts trial of experimental coronavirus vaccine, eyes launch next year

FRANKFURT (Reuters) - Unlisted German biotech firm CureVac will become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in the country, eyeing a potential approval in mid-2021.The trial launch, first reported by Reuters on Tuesday, will see 144 participants in Germany and Belgium receive different dosages of the vaccine and a further 24 getting a placebo. First meaningful results could be available in September or October, and approval could..